Capillary Biomedical Receives $1.5 Million from Helmsley Charitable Trust for Clinical Trials of New Insulin Infusion Technology
IRVINE, Calif.–(BUSINESS WIRE)–Capillary Biomedical, Inc. (CapBio) has announced that it has received a $1.5 million program-related investment in the form of a loan from The Leona M. and Harry B. Helmsley Charitable Trust (Helmsley). The use of funds includes clinical studies of CapBio’s novel SteadiFlowtm technology to evaluate the potential for extended-wear of insulin infusion sets by people with Type 1 diabetes for 7 days and beyond.
CapBio’s SteadiSettm infusion set, powered by its SteadiFlow technology platform, is designed to increase the wear time of insulin infusion sets by addressing the common causes of infusion site failure. Infusion sets are a key component of recently introduced automated insulin delivery (AID) systems that use continuous glucose monitoring (CGM) sensors to guide insulin pump therapy. Sets are designed to be changed every two to three days, but sites often fail sooner. Infusion site failures can lead to diabetic